Keating Financial Advisory Services’s AbbVie ABBV Stock Holding History

Keating Financial Advisory Services’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21M	Buy	4,827 +274	+6%	+$59K	0.16%	93
2026 Q1	$990K	Buy	4,553 +42	+0.9%	+$9.32K	0.16%	90
2025 Q4	$1.03M	Buy	+4,511	New	+$1.03M	0.14%	127

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Keating Financial Advisory Services's ABBV Position: Q2 2026 in Review

Keating Financial Advisory Services increased its AbbVie (ABBV) stake by 6% in Q2 2026, buying an estimated $59K and bringing the position to 4,827 shares worth $1.21M. The position accounts for 0.16% of the portfolio, ranked #93.

Keating Financial Advisory Services first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Keating Financial Advisory Services held 4,827 shares of AbbVie worth $1.21M as of Q2 2026.
Keating Financial Advisory Services bought 274 AbbVie shares in Q2 2026, an estimated $59K.
AbbVie made up 0.16% of Keating Financial Advisory Services's portfolio in Q2 2026, its #93 holding.
Keating Financial Advisory Services first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.